Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model

Fig. 5

Vaccine effects on tumor infiltrating lymphocytes (TILs). Vaccinations occurred on days 3 and 10 post challenge. Mice were sacrificed on day 17 and lymphocyte-enriched tumor suspensions were analyzed by flow cytometry. a shows CD8+ TILs and b CD4+ TILs. Data show one representative experiment with 3–5 mice per group. Two independent experiments were performed. All three vaccine formulations have significantly higher CD4 and CD8 TILs compared to mock vaccination but not to each other, as assessed by ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page